Informational only. Not medical advice.INFORMATIONAL PLATFORM ONLY — NOT MEDICAL ADVICE, DIAGNOSIS, OR TREATMENT
A novel triple-agonist peptide targeting GLP-1, GIP, and glucagon receptors, demonstrating the highest weight loss of any anti-obesity medication tested to date in Phase 2 trials.
Lowest Price
$49.99
Highest Price
$2020.60
Average Price
$553.40
Potential Savings
71%
across 12 options
Check formulation: Lyophilized powder requires reconstitution before use. Pre-mixed solutions are more convenient but may have a shorter shelf life and higher prices.
Compare per-mg cost: Different strengths and quantities make direct price comparison difficult. Calculate the per-milligram cost to find the true best value.
Verify COAs: Look for vendors that publish per-batch Certificates of Analysis from named, accredited labs. Every vendor on this page is verified for endotoxin testing — not just HPLC purity.
Jastreboff et al. (NEJM, 2023) reported the Phase 2 trial results: 24.2% body weight loss at 12mg weekly over 48 weeks. Significant reductions in hepatic steatosis were also observed (fatty liver improved markedly due to glucagon receptor activation). Phase 3 TRIUMPH trials are ongoing with results expected 2025-2026. If approved, retatrutide would be the first triple-agonist obesity medication and potentially the most effective weight loss drug ever developed.
This platform provides informational tools only, not medical advice.
Retatrutide, a GIP, GLP-1, and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-comparator-controlled, parallel-group, phase 2 trial
2023
Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease
2023
GLP-1/GIP/glucagon receptor triagonism for the treatment of obesity: challenges and opportunities
Prices verified as of April 2026. Actual prices may vary. For research use only.
Prices are estimates and may vary. For research use only. We may earn a commission on purchases through affiliate links. Not medical advice.
2023